RNS Number : 8440U
Legal & General UCITS ETF PLC
01 August 2020
| Funds |
Date |
ISIN code |
Shares in Issue |
Currency |
Net Asset Value |
NAV/per share Base |
| L&G US Equity UCITS ETF |
31/07/2020 |
IE00BFXR5Q31 |
12167267 |
USD |
150380923.19 |
12.359 |
| L&G UK Equity UCITS ETF |
31/07/2020 |
IE00BFXR5R48 |
1200000 |
GBP |
10464581.91 |
8.720 |
| L&G Global Equity UCITS ETF |
31/07/2020 |
IE00BFXR5S54 |
2900000 |
USD |
34096860.24 |
11.758 |
| L&G Japan Equity UCITS ETF |
31/07/2020 |
IE00BFXR5T61 |
11185000 |
USD |
114499727.74 |
10.237 |
| L&G Europe ex UK Equity UCITS ETF |
31/07/2020 |
IE00BFXR5V83 |
9360988 |
EUR |
99305983.76 |
10.608 |
| L&G Asia Pacific ex Japan Equity UCITS ETF |
31/07/2020 |
IE00BFXR5W90 |
5181427 |
USD |
54793602.29 |
10.575 |
| L&G Clean Water UCITS ETF |
31/07/2020 |
IE00BK5BC891 |
1500000 |
USD |
16284060.05 |
10.856 |
| L&G Artificial Intelligence UCITS ETF |
31/07/2020 |
IE00BK5BCD43 |
7946000 |
USD |
109406662.80 |
13.769 |
| L&G Healthcare Innovation UCITS ETF |
31/07/2020 |
IE00BK5BC677 |
3000000 |
USD |
41365688.89 |
13.789 |
| L&G Pharma Breakthrough UCITS ETF |
31/07/2020 |
IE00BF0H7608 |
2150000 |
USD |
25841456.78 |
12.019 |
| L&G Europe Equity (Responsible Exclusions) UCITS ETF |
31/07/2020 |
IE00BKLTRN76 |
9200000 |
EUR |
92427042.60 |
10.046 |
| L&G US Equity (Responsible Exclusions) UCITS ETF |
31/07/2020 |
IE00BKLWY790 |
57800000 |
USD |
645317234.88 |
11.165 |
| L&G Battery Value-Chain UCITS ETF |
31/07/2020 |
IE00BF0M2Z96 |
13200000 |
USD |
131957606.31 |
9.997 |
| L&G Ecommerce Logistics UCITS ETF |
31/07/2020 |
IE00BF0M6N54 |
9600000 |
USD |
108790345.71 |
11.332 |
| L&G ROBO Global Robotics and Automation UCITS ETF |
31/07/2020 |
IE00BMW3QX54 |
46830616 |
USD |
849922998.09 |
18.149 |
| L&G Cyber Security UCITS ETF |
31/07/2020 |
IE00BYPLS672 |
82611776 |
USD |
1682596482.98 |
20.368 |
|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
[email protected] or visit
www.rns.com.
END
NAVGZGFNFMDGGZZ
